Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.

@article{Pander2010CorrelationOF,
  title={Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.},
  author={Jan Pander and Hans A.J. Gelderblom and Ninja F Antonini and Jolien Tol and Johan Hjm van Krieken and Tahar Van der Straaten and Cornelis J A Punt and Henk-Jan Guchelaar},
  journal={European journal of cancer},
  year={2010},
  volume={46 10},
  pages={1829-34}
}
BACKGROUND Next to KRAS mutation status, additional predictive markers are needed for the response to cetuximab in patients with metastatic colorectal cancer (mCRC). Previous studies indicated that germline polymorphisms in specific genes may predict efficacy and toxicity of cetuximab in mCRC patients. METHODS Germline DNA was isolated from 246 KRAS wild-type mCRC patients who were treated in the phase III CAIRO2 study with chemotherapy and bevacizumab alone or with the addition of cetuximab… CONTINUE READING